Would you use sequential CDK 4/6 inhibitors in HR-positive metastatic breast CA in successive lines of therapy?  

In MONALEESA-2, it appears ~22% of those in the ribcociclib group received a subsequent CDK4/6 inhibitor. What was the rationale and could this have impacted the OS benefit?

If you use sequential CDK4/6 inhibitors, do you change the endocrine agent?



Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at The Karches Center for Oncology Research, Feinstein Institutes for Medical Research
Clinical experience has demonstrated that stopping...
Medical Oncologist at Harvard Medical School
Agree with the comments above and below - ultimate...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR
Prior to using SERDs, it is important to make sure...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution